Free tool
Drug Trial Radar: Endocrinology and women's health
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
328
Completed, industry sponsors, Endocrinology and women's health, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed328
328 trials
Showing 1 to 25, recently updated first.
- A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through MenopausePivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT06206408 · 410 participants · Start Feb 16, 2024 · Primary completion Oct 22, 2025
Drug: Fezolinetant; Placebo · For: Hot Flashes
Sites: Chita-gun, Japan; Kōnan, Japan; Nagoya, Japan · 64 sites in all
- A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)Pivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03811535 · 200 participants · Start May 20, 2019 · Primary completion Nov 10, 2021
Drug: Somapacitan; Norditropin® · For: Growth Hormone Deficiency in Children
Sites: Birmingham, Alabama; Los Angeles, California; Madera, California · 139 sites in all
- A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With OsteoporosisPivotal-lookingCompleted
NCT05067335 · 327 participants · Start Oct 21, 2021 · Primary completion Nov 9, 2023
Drug: Romosozumab; Placebo · For: Osteoporosis
Sites: Beijing, China; Chengdu, China; Foshan, China · 30 sites in all
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyPivotal-lookingCompleted
Camurus ABIndustry
NCT04076462 · 72 participants · Start Aug 19, 2019 · Primary completion May 2, 2023
Drug: CAM2029 (octreotide subcutaneous depot); Matching placebo · For: Acromegaly
Sites: Los Angeles, California; Palo Alto, California; Miami, Florida · 63 sites in all
- A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT06804590 · 280 participants · Start Nov 16, 2024 · Primary completion Apr 24, 2026
Drug: 9MW0311; Prolia® · For: Postmenopausal Women Osteoporosis
Sites: Beijing, China
- A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone DeficiencyPivotal-lookingCompleted
Ascendis Pharma Endocrinology Division A/SIndustry
NCT03305016 · 146 participants · Start Nov 13, 2017 · Primary completion Mar 19, 2019
Drug: TransCon hGH · For: Growth Hormone Deficiency, Pediatric; Endocrine System Diseases; Hormone Deficiency and 1 more
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 24 sites in all
- A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical TrialPivotal-lookingCompleted
Ascendis Pharma A/SIndustry
NCT03344458 · 298 participants · Start Dec 19, 2017 · Primary completion Feb 21, 2023
Drug: TransCon hGH · For: Growth Hormone Deficiency, Pediatric; Endocrine System Diseases; Hormone Deficiency and 1 more
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 42 sites in all
- A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)Pivotal-lookingCompleted
Ascendis Pharma Endocrinology Division A/SIndustry
NCT02781727 · 162 participants · Start Dec 13, 2016 · Primary completion Jan 17, 2019
Drug: Once weekly subcutaneous injection of TransCon hGH; Once daily subcutaneous injection of Genotropin · For: Growth Hormone Deficiency, Pediatric; hGH (Human Growth Hormone); Endocrine System Diseases and 2 more
Sites: Birmingham, Alabama; Little Rock, Arkansas; Los Angeles, California · 53 sites in all
- A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone DeficiencyPivotal-lookingCompleted
Ascendis Pharma Endocrinology Division A/SIndustry
NCT04615273 · 264 participants · Start Dec 3, 2020 · Primary completion Nov 2, 2023
Drug: Lonapegsomatropin; Somatropin · For: Growth Hormone Deficiency; Endocrine System Diseases; Hormone Deficiency
Sites: Birmingham, Alabama; Phoenix, Arizona; Fresno, California · 113 sites in all
- A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone DeficiencyPivotal-lookingCompleted
Ascendis Pharma Endocrinology Division A/SIndustry
NCT05171855 · 220 participants · Start Dec 16, 2021 · Primary completion Dec 23, 2024
Drug: Lonapegsomatropin · For: Adult Growth Hormone Deficiency; Endocrine System Diseases; Hormone Deficiency
Sites: Phoenix, Arizona; Torrance, California; Chicago, Illinois · 85 sites in all
- Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for PregnancyPivotal-lookingCompleted
Sumitomo Pharma Switzerland GmbHIndustry
NCT04756037 · 1,164 participants · Start Mar 18, 2021 · Primary completion Feb 25, 2025
Drug: Relugolix Combination Therapy · For: Contraception
Sites: Mobile, Alabama; Chandler, Arizona; Mesa, Arizona · 112 sites in all
- A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through MenopausePivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT06206421 · 277 participants · Start Feb 22, 2024 · Primary completion Mar 19, 2026
Drug: Fezolinetant; Placebo · For: Hot Flashes
Sites: Nagoya, Japan; Matsudo-shi, Japan; Fukuoka, Japan · 24 sites in all
BayerBayer (BAYRY)
NCT05042362 · 396 participants · Start Aug 27, 2021 · Primary completion Jul 25, 2023
Drug: Elinzanetant (BAY3427080); Placebo · For: Vasomotor Symptoms Associated With Menopause; Hot Flashes
Sites: Birmingham, Alabama; Mesa, Arizona; Scottsdale, Arizona · 99 sites in all
BayerBayer (BAYRY)
NCT05099159 · 400 participants · Start Oct 29, 2021 · Primary completion Jun 13, 2023
Drug: Elinzanetant (BAY3427080); Placebo · For: Vasomotor Symptoms Associated With Menopause; Hot Flashes
Sites: Birmingham, Alabama; Mobile, Alabama; Peoria, Arizona · 113 sites in all
- A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®Pivotal-lookingCompleted
Enzene Biosciences Ltd.Industry
NCT05405725 · 504 participants · Start Jul 4, 2022 · Primary completion Jul 18, 2024
Drug: ENZ215; Prolia · For: Postmenopausal Osteoporosis
Sites: Plovdiv, Bulgaria; Rousse, Bulgaria; Sofia, Bulgaria · 48 sites in all
- A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.Pivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04970654 · 110 participants · Start Jul 22, 2021 · Primary completion Nov 17, 2023
Drug: somapacitan; Norditropin® · For: Growth Hormone Deficiency in Children
Sites: Hefei, China; Beijing, China; Xiamen, China · 32 sites in all
- Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)Pivotal-lookingCompleted
EstetraIndustry
NCT04090957 · 1,015 participants · Start Sep 27, 2019 · Primary completion Aug 18, 2022
Drug: Estetrol oral tablet; Placebo oral tablet · For: Vasomotor Symptoms; Menopausal Symptoms
Sites: Birmingham, Alabama; Dothan, Alabama; Phoenix, Arizona · 117 sites in all
- A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyPivotal-lookingCompleted
Camurus ABIndustry
NCT04125836 · 135 participants · Start Oct 10, 2019 · Primary completion Apr 24, 2025
Drug: CAM2029 (octreotide subcutaneous depot) · For: Acromegaly
Sites: Los Angeles, California; Palo Alto, California; Miami, Florida · 68 sites in all
BayerBayer (BAYRY)
NCT05030584 · 628 participants · Start Aug 27, 2021 · Primary completion Mar 29, 2023
Drug: Elinzanetant (BAY3427080); Placebo · For: Vasomotor Symptoms Associated With Menopause; Hot Flashes
Sites: Mobile, Alabama; Mesa, Arizona; Garden Grove, California · 86 sites in all
- A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated PainPivotal-lookingCompleted
Nanjing Chia-tai Tianqing PharmaceuticalIndustry
NCT06076486 · 202 participants · Start Sep 14, 2023 · Primary completion Nov 22, 2024
Drug: Elagolix; Elagolix placebo · For: Endometriosis
Sites: Beijing, China
- Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
Biocon Biologics UK LtdIndustry
NCT05345691 · 479 participants · Start May 24, 2022 · Primary completion Jun 12, 2024
Drug: Bmab 1000; Prolia® · For: Postmenopausal Women With Osteoporosis
Sites: Cambridge, United Kingdom
- A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasPivotal-lookingCompleted
Corcept TherapeuticsIndustry
NCT04308590 · 137 participants · Start Jul 27, 2020 · Primary completion Sep 19, 2024
Drug: Relacorilant · For: Hypercortisolism
Sites: Birmingham, Alabama; Stanford, California; Torrance, California · 45 sites in all
- Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenPivotal-lookingCompleted
OPKO Health, Inc.Industry
NCT02968004 · 224 participants · Start Dec 2016 · Primary completion Aug 2019
Drug: MOD-4023; Somatropin · For: Pediatric Growth Hormone Deficiency
Sites: Orange, California; Aurora, Colorado; Centennial, Colorado · 81 sites in all
- A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromePivotal-lookingCompleted
Corcept TherapeuticsIndustry
NCT03697109 · 152 participants · Start Nov 15, 2018 · Primary completion Apr 8, 2024
Drug: Relacorilant · For: Cushing Syndrome
Sites: Phoenix, Arizona; Los Angeles, California; Torrance, California · 64 sites in all
- To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture RiskPivotal-lookingCompleted
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07028320 · 493 participants · Start Dec 3, 2021 · Primary completion Dec 30, 2023
Drug: SAL056 (56.5μg); Alendronate · For: Postmenopausal Women With Osteoporosis
Sites: Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.